All In Biotech

Drug Trial Radar · NCT02826343

New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)

Xe129 Magnetic Resonance Imaging of the Lung: A New Technology to Assess Treatment for COPD

Last checked: Nov 20, 2026Latest source record: Nov 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

May 1, 2016

Primary completion

Jun 15, 2018

Study completion Jun 15, 2018

Sponsor

Lead sponsor
University of VirginiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institutes of Health (NIH)
First posted
Jul 11, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

First, the investigators will image patients with hyperpolarized xenon (Xe) magnetic resonance imaging (MRI) to develop the technique of hyperpolarized xenon MRI at the University of Virginia (UVA). Magnetic Resonance (MR) sequences will need to be developed and optimized for the equipment at UVA. These sequences will need to be evaluated in healthy adults for comparison with results obtained and in adults with lung diseases to optimize the sequences for the detection and evaluation of lung diseases. The MR pulse sequences need to be optimized for the parameters of a human MR coil and the gas exchange characteristics in healthy and diseased lungs. Second, the investigators propose to exploit the power of Xe129 MRI as a diagnostic tool to monitor therapeutic responses of a combination inhaler, Advair, which contains a long-acting beta-adrenoceptor agonist (LABA) and an inhaled corticosteroid (ICS) - two major classes of the current COPD therapeutics. The investigators will characterize the functional changes of the lungs with COPD at baseline, and investigate the responses of the lungs to the treatment after a three-month trial. Also the investigators will compare corresponding results obtained by Xe129 dissolved phase (DP) MRI to the results obtained by gadolinium-based dynamic contrast-enhanced perfusion MRI (perfusion MRI) and high resolution computed tomography (HRCT) of the lung to indirectly validate the Xe129 DP MRI technique. The investigators anticipate that the results from this project will greatly improve the investigators understanding of the lung functional responses of COPD subjects to current therapeutics. Also, the investigators expect that this project will provide evidence to consider Xe129 MRI as a diagnostic strategy to assess and monitor therapeutic responses of existing and new pharmaceuticals, and thus Xe129 MRI will stimulate development of novel therapies for COPD in the future

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • Xenon129 MRI imagingDrug

    subjects will receive at baseline and 3 month post Advair intervention (See next intervention)

  • Gadolinium MRIDrug

    subjects will receive at baseline and 3 month post Advair intervention (See next intervention)

  • Advair (250mcg/50mcg) one puff twice a dayDrug

    subjects will receive for 3 month duration between baseline and 3 month post Xenon129 MRI imaging and Gadolinium MRI.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement in pulmonary airflow physiology detected by Xenon129 MRITime frame: From baseline to 3 month post treatment with Advair
  2. Improvement in pulmonary gas exchange physiology detected by Xenon129 MRITime frame: From baseline to 3 month post treatment with Advair

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Virginia

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.